医学
肺癌
酪氨酸激酶
内科学
癌症
肺
肿瘤科
呼吸道疾病
酪氨酸激酶抑制剂
基因
肺癌的治疗
癌
突变
生存分析
激酶
作者
Cian Murphy,Tej Pandya,Charles Swanton,Benjamin Solomon
出处
期刊:JAMA
[American Medical Association]
日期:2025-10-20
卷期号:334 (20): 1836-1836
被引量:8
标识
DOI:10.1001/jama.2025.17695
摘要
Lung cancer in nonsmoking individuals accounts for 15% to 20% of lung cancer cases worldwide. Among patients with lung cancer, nonsmoking individuals are more likely to have genomic alterations such as EGFR mutations or ALK gene rearrangements, and these patients have improved survival when treated with tyrosine kinase inhibitors compared with chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI